| 1. |
- Angelika Ihle, Michaela, et al.
(författare)
-
HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat.
- 2016
-
Ingår i: The journal of pathology. Clinical research. - : Wiley. - 2056-4538. ; 2:2, s. 59-71
-
Tidskriftsartikel (refereegranskat)abstract
- Histone deacetylases (HDAC) are key players in epigenetic regulation of gene expression and HDAC inhibitor (HDACi) treatment seems to be a promising anticancer therapy in many human tumours, including soft tissue sarcomas. HR23b has been shown to be a potential biomarker for sensitivity to HDACi therapy in cutaneous T-cell lymphoma and hepatocellular carcinoma. We aimed to evaluate HR23b as a candidate biomarker for HDACi response in sarcomas and gastrointestinal stromal tumours (GIST). Therefore, HR23b expression was analysed comprehensively by western blot in sarcoma and GIST cell lines covering all major clinically relevant subtypes. MTT assay and ApoTox-Glo(TM) Triplex assay were performed after treatment with vorinostat, belinostat, mocetinostat and entinostat. HR23b protein expression was measured under HDACi treatment. Furthermore, HR23b expression levels were immunohistochemically determined in a large set of 523 clinical samples from sarcoma and GIST patients. Western blot analyses showed that sarcomas differ significantly in their expression of HR23b protein. All HDACi were able to regulate proliferation and apoptosis in vitro. Sensitivity to vorinostat correlated significantly with HR23b protein expression. Immunohistochemical prevalence screening in clinical samples of relevant adult-type tumours revealed that 12.5% of sarcomas (among them malignant peripheral nerve sheath tumours, pleomorphic liposarcomas, leiomyosarcomas, dedifferentiated liposarcomas, synovial sarcomas and angiosarcomas) and 23.2% of GIST show high HR23b expression. Therefore, HDACi have antiproliferative and proapoptotic effects in sarcomas depending on the expression level of HR23b. These findings suggest that HR23b represents a candidate biomarker for HDACi sensitivity in certain sarcoma types and in GIST.
|
|
| 3. |
- Sugiyama, Jun, et al.
(författare)
-
Search for a space charge layer in thin film battery materials with low-energy muons
- 2023
-
Ingår i: Journal of Physics: Conference Series. - : IOP Publishing. - 1742-6588 .- 1742-6596. ; 2462:1
-
Konferensbidrag (refereegranskat)abstract
- In an all solid state Li-ion battery, it is crucial to reduce ionic resistivity at the interface between the electrode and the electrolyte in order to enhance Li+ mobility across the interface. Recent first principles calculations predict the presence of a space-charge layer (SCL) at the interface due to the difference in the Li+ chemical potential at the interface between two different materials, as in the metal-semiconductor junction in electronic devices. However, the presence of SCL has never been experimentally observed. Our first attempt in a fresh multilayer sample, Cu(10 nm)/Li3PO4(50 nm)/LiCoO2(100 nm) on a sapphire substrate, with low-energy μ +SR (LE μ +SR) revealed a gradual change in the nuclear magnetic field distribution width as a function of implantation depth even across the interface between Li3PO4 and LiCoO2. This implies that the change in the field distribution width at SCL of the sample is too small to be detected by LE μ +SR.
|
|
